NCT06206902View on ClinicalTrials.gov

F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

December 31, 2025

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

After preconditioning with chemotherapy, F01 will be evaluated.

Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 300 mg/ m\^2 (D-5\~D-3)

Trial Locations (2)

Unknown

RECRUITING

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

RECRUITING

The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
collaborator

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

lead

Shanghai Simnova Biotechnology Co.,Ltd.

INDUSTRY